HAIER BIOMEDICAL(SH:688139) Shang Hai Zheng Quan Bao·2025-03-28 23:26Core Viewpoint - The company focuses on providing integrated digital solutions in the life sciences and medical innovation sectors, leveraging advanced technologies to enhance user experience and drive industry transformation [5][6][25]. Company Overview - The company operates in two main segments: life sciences and medical innovation, offering solutions such as smart laboratories and digital hospitals [5]. - The company has established a strong global presence, with products and solutions applied in over 150 countries and regions [6][26]. Business Model - The company maintains a comprehensive control over the entire process from research and development to sales and after-sales service [7]. - The procurement process involves rigorous supplier qualification and just-in-time inventory management [8]. Industry Situation - The life sciences and medical innovation sectors are experiencing growth driven by increased demand for integrated solutions and advancements in technology [12][21]. - The global life sciences tools market is projected to reach $330.69 billion by 2030, with significant growth in the Asia-Pacific region [12]. Technological Advancements - The company has developed six major technology platforms and holds 1,595 patents, positioning itself as a leader in biomedicine and low-temperature technology [25]. - The integration of IoT, cloud computing, and AI into the company's offerings is expected to enhance operational efficiency and user experience [27][28]. Financial Highlights - The company plans to distribute a cash dividend of 4.7 yuan per 10 shares, totaling approximately 147.8 million yuan [3]. Future Development Trends - The industry is shifting towards automation and intelligent solutions, with a focus on enhancing operational efficiency and reducing costs [28][29]. - The company aims to capitalize on the growing demand for digital solutions in healthcare, driven by national policies and technological advancements [17][19][31].